Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · IEX Real-Time Price · USD
2.190
+0.010 (0.46%)
Jul 22, 2024, 10:13 AM EDT - Market open
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 28 employees as of December 31, 2023. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$887,750
Market Cap
136.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Harvard Bioscience | 416 |
Amylyx Pharmaceuticals | 384 |
Cellectis | 221 |
Electromed | 170 |
Inventiva | 123 |
Invivyd | 95 |
Vigil Neuroscience | 69 |
DiaMedica Therapeutics | 19 |
CRVS News
- 7 weeks ago - Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering - GlobeNewsWire
- 3 months ago - Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 4 months ago - Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 - GlobeNewsWire
- 5 months ago - Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases - GlobeNewsWire